1. Home
  2. GOSS vs BDSX Comparison

GOSS vs BDSX Comparison

Compare GOSS & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GOSS
  • BDSX
  • Stock Information
  • Founded
  • GOSS 2015
  • BDSX 2005
  • Country
  • GOSS United States
  • BDSX United States
  • Employees
  • GOSS N/A
  • BDSX N/A
  • Industry
  • GOSS Biotechnology: Pharmaceutical Preparations
  • BDSX Precision Instruments
  • Sector
  • GOSS Health Care
  • BDSX Health Care
  • Exchange
  • GOSS Nasdaq
  • BDSX Nasdaq
  • Market Cap
  • GOSS 212.8M
  • BDSX 215.3M
  • IPO Year
  • GOSS 2019
  • BDSX 2020
  • Fundamental
  • Price
  • GOSS $1.40
  • BDSX $0.88
  • Analyst Decision
  • GOSS Strong Buy
  • BDSX Strong Buy
  • Analyst Count
  • GOSS 5
  • BDSX 4
  • Target Price
  • GOSS $9.20
  • BDSX $3.08
  • AVG Volume (30 Days)
  • GOSS 1.6M
  • BDSX 359.8K
  • Earning Date
  • GOSS 03-04-2025
  • BDSX 03-03-2025
  • Dividend Yield
  • GOSS N/A
  • BDSX N/A
  • EPS Growth
  • GOSS N/A
  • BDSX N/A
  • EPS
  • GOSS N/A
  • BDSX N/A
  • Revenue
  • GOSS $105,322,000.00
  • BDSX $65,562,000.00
  • Revenue This Year
  • GOSS N/A
  • BDSX $46.97
  • Revenue Next Year
  • GOSS N/A
  • BDSX $31.65
  • P/E Ratio
  • GOSS N/A
  • BDSX N/A
  • Revenue Growth
  • GOSS N/A
  • BDSX 48.92
  • 52 Week Low
  • GOSS $0.50
  • BDSX $0.86
  • 52 Week High
  • GOSS $1.60
  • BDSX $2.04
  • Technical
  • Relative Strength Index (RSI)
  • GOSS 67.09
  • BDSX 30.29
  • Support Level
  • GOSS $1.37
  • BDSX $0.90
  • Resistance Level
  • GOSS $1.55
  • BDSX $1.00
  • Average True Range (ATR)
  • GOSS 0.13
  • BDSX 0.07
  • MACD
  • GOSS 0.03
  • BDSX 0.00
  • Stochastic Oscillator
  • GOSS 75.81
  • BDSX 3.41

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: